AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04080843
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin 130 mg/m2,D1
Trial: NCT04091412
Drug: Butylphthalide Soft Capsules
RxNorm normalized name: Butylphthalide
DrugBank: Butylphthalide (DB12749)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The first class national new drug for the Treatment of Mild to Moderate Acute Ischemic Stroke; Long-term application can improve collateral circulation.
Trial: NCT01298505
Drug: PF-03654764 5mg plus fexofenadine 60mg
RxNorm normalized name: fexofenadine hydrochloride 60 MG
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PF-03654764 5mg plus fexofenadine 60mg twice daily for 7 days
Trial: NCT00413270
Drug: nilotinib
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00459342
Drug: dasatinib
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given orally
Trial: NCT02636270
Drug: Increlex
RxNorm normalized name: Increlex
DrugBank: Mecasermin (DB01277)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Treat PAPP-A2 deficient patients with Increlex
Trial: NCT03534310
Drug: LIRAGLUTIDE 3 Mg/0.5 mL (18 Mg/3 mL) SUB-Q PEN INJECTOR (ML)
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01471340
Drug: Mometasone Furoate/Formoterol MDI 100/5 mcg
DrugBank: Mometasone (DB00764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two inhalations BID
Trial: NCT01471340
Drug: Mometasone Furoate/Formoterol MDI 200/5 mcg
DrugBank: Mometasone (DB00764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two inhalations BID
Trial: NCT01471340
Drug: Mometasone Furoate MDI 100 mcg
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone (DB00764)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: two inhalations BID
Trial: NCT01471340
Drug: Mometasone Furoate MDI 200 mcg
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone (DB00764)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: two inhalations BID
Trial: NCT01471340
Drug: Albuterol 90 mcg /salbutamol 100 mcg HFA MDI
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: use as needed for asthma symptoms
Trial: NCT01471340
Drug: Prednisone/prednisolone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisone/prednisolone used only as an emergency rescue medication at the discretion of the investigator
Trial: NCT02572557
Drug: Liquid nitrogen
DrugBank: Nitrogen (DB09152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TruFreeze Spray CryoTherapy using liquid nitrogen
Trial: NCT02621957
Drug: GDC-0810
RxNorm normalized name: GDC-0810
DrugBank: GDC-0810 (DB12253)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During Period 2 subjects will be administered an oral 600 mg dose GDC-0810 daily beginning on Day 5 for 4 consecutive days (from Days 5 to 8, inclusive).
Trial: NCT03469284
Drug: Methylene Blue
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given lower dose PO
Trial: NCT01567852
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketamine (1.5mg/kg) will be given for induction, with room to titrate up to induction effect
Trial: NCT01567852
Drug: Methohexital
RxNorm normalized name: Methohexital
DrugBank: Methohexital (DB00474)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methohexital (1.5mg/kg) will be given for induction
Trial: NCT01737398
Drug: Inotersen
RxNorm normalized name: INOTERSEN
DrugBank: Inotersen (DB14713)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03306329
Drug: DNS-7801 (low-dose)
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DNS-7801 (low-dose) tablets administered once daily.
Trial: NCT03306329
Drug: DNS-7801 (high dose)
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DNS-7801 (high dose) tablets administered once daily.
Trial: NCT03469284
Drug: Methylene Blue
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given medium dose PO
Trial: NCT03469284
Drug: Methylene Blue
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given higher dose PO
Trial: NCT01834508
Drug: oral entecavir 0.5mg daily and adefovir 10mg daily for 144 weeks
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02522858
Drug: Atropine
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To evaluate the effectiveness of atropine on prevention bradycardia,atropine 0.01\~0.03mg/kg up to 0.5mg would be injected intravenously just before starting loading dose of dexmedetomidine in group A.~During operation, heart rate decreasing 30% from initial heart rate or under 40/min would be regarded as bradycardia needing treatment, and atropine 0.5mg will be injected intravenously. This intervention would be applied to both group.
Trial: NCT02522858
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine is a highly selective a2 adrenergic receptor antagonist used as sedative agent. After confirming the fixation level of spinal anesthesia, the loading dose(0.6ug/kg) of dexmedetomidine which is diluted with normal saline as 4ug/mL would be started for 10 minutes.Maintenance dose(0.25ug/kg/hr) would be continued after loading dose.
Trial: NCT01858649
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab 5 mg/kg in 100 ml NaCl 0.9% IV infusion 3 to 5 cycles. No bevacizumab for ultimate cycle .
Trial: NCT01858649
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oxaliplatin 85 mg/m² in 150 ml NaCl 0.9%, IV infusion 3 to 6 cycles
Trial: NCT01858649
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan 180 mg/m² in 150 ml NaCl 0.9%, IV infusion 3 to 6 cycles
Trial: NCT00368394
Drug: Insulin glulisine
RxNorm normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02522858
Drug: Ephedrine
RxNorm normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systolic blood pressure decreasing 30% from basal blood pressure or under 90 mm Hg would be regarded as hypotension needing treatment, and ephedrine 5mg will be injected intravenously.
Trial: NCT00667472
Drug: Ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Combined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks
Trial: NCT00116844
Drug: Valaciclovir
RxNorm normalized name: valaciclovir
DrugBank: Valaciclovir (DB00577)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valtrex 1g once daily
Trial: NCT02252419
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone will be administered.
Trial: NCT02252419
Drug: Paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paracetamol will be administered.
Trial: NCT01705743
Drug: Sevoflurane+Nitrous oxide
RxNorm normalized name: Nitrous Oxide
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60% nitrous oxide +40% oxygen+ Sevoflurane
Trial: NCT01705743
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100% oxygen+ Sevoflurane
Trial: NCT04539314
Drug: Bupivacain
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: We will carry out the TAP block using 0.5 ml/ kg bupivacaine 0.25%
Trial: NCT04539314
Drug: Dexmedetomidine o.5 μg
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: We will carry out the TAP block using using 0.5 ml/ kg bupivacaine 0.25% with dexmedetomidine 0.5 μg / kg
Trial: NCT04539314
Drug: Dexmedetomidine 1 μg
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: We will carry out the TAP block using using 0.5 ml/ kg bupivacaine 0.25% with dexmedetomidine 1 μg / kg
Trial: NCT02833688
Drug: dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: dexmedetomidine 2mg is diluted in 0.9% sodium chloride with the concentration of 4 ug ml-1 is administered with an loading dose of 0.5ug kg-1 of 10 min, and maintained with infusion rate of 0.5 ug kg-1 h-1. The infusion is ceased after the resection of the hepatic issues.
Trial: NCT02833688
Drug: 0.9% sodium chloride
RxNorm normalized name: LMD with 0.9% Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride is administered with an loading dose of 0.5ug kg-1 of 10 min, and maintained with infusion rate of 0.5 ug kg-1 h-1. The infusion is ceased after the resection of the hepatic issues.
Trial: NCT00491400
Drug: Fenofibrate
RxNorm normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 140 mg/day for 8 weeks
Trial: NCT00491400
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg/day for 8 weeks
Trial: NCT04501640
Drug: mirabegron
RxNorm normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral adminstration
Trial: NCT03605082
Drug: UCB0107
RxNorm normalized name: Immunoglobulin g4 (226-proline), anti-(human tau protein) (human-rattus norvegicus monoclonal ucb0107 .gamma.4-chain), disulfide with human-rattus norvegicus monoclonal ucb0107 .kappa.-chain, dimer
DrugBank: Bepranemab (DB17945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Pharmaceutical form: solution for infusion~* Route of administration: intravenous use
Trial: NCT01521962
Drug: Alogliptin
RxNorm normalized name: Alogliptin
DrugBank: Alogliptin (DB06203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alogliptin tablets
Trial: NCT01521962
Drug: Insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin injection
Trial: NCT01523392
Drug: Ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Min - 90mg/Max - 180mg tablets (loading dose)
Trial: NCT01523392
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 75mg (once daily)/Max - 600mg tablets (loading dose)
Trial: NCT02699879
Drug: Pirfenidone
RxNorm normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pirfenidone will be administered according to the physician discretion as part of standard care.
Trial: NCT00166309
Drug: FEIBA and NovoSeven
RxNorm normalized name: Feiba
DrugBank: Anti-inhibitor coagulant complex (DB13151)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02968693
Drug: Vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vancomycin powder was added into the combination therapy group and PMMA groups
Trial: NCT02013310
Drug: HT-0712
RxNorm normalized name: HT-0712
DrugBank: HT-0712 (DB11650)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04023071
Drug: FT516
RxNorm normalized name: FT516
DrugBank: FT516 (DB15732)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental Interventional Therapy
Trial: NCT04023071
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Monoclonal Antibody
Trial: NCT05121714
Drug: Fluvoxamine
RxNorm normalized name: Fluvoxamine
DrugBank: Fluvoxamine (DB00176)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: his is a 2 part, fixed-sequence open-label, crossover study to evaluate the potential CYP1A2-mediated drug-drug interactions (DDI), safety, and tolerability of ABX464 combined with a known CYP1A2 inhibitor (fluvoxamine).
Trial: NCT04023071
Drug: Obinutuzumab
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Monoclonal Antibody
Trial: NCT04023071
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conditioning agent
Trial: NCT04023071
Drug: IL-2
RxNorm normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biologic response modifier
Trial: NCT04023071
Drug: Bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Conditioning agent
Trial: NCT04997707
Drug: Propofol Abbott
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: in a rate of 75-100 μg/kg/min in P group, and 25μg/kg/min in BA group
Trial: NCT04997707
Drug: Sevoflurane Inhalation Solution
RxNorm normalized name: sevoflurane Inhalation Solution
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: in BA group will be calculated by age-adjusted end - tidal MAC as follows: for age of 18-25 years, 26-40 years and ≥40 years MAC will be 2.6%, 2.2% and 1.8% respectively then final concentration to be delivered will be 0.2% lower than calculated half MAC.
Trial: NCT00893100
Drug: Diltiazem
RxNorm normalized name: Diltiazem
DrugBank: Diltiazem (DB00343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2%,3 times daily
Trial: NCT04726657
Drug: Premixed Insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Premixed Insulin Analog Biphasic Aspart 30
Trial: NCT00788541
Drug: Anecortave Acetate Sterile Suspension, 6 mg/mL
DrugBank: Anecortave acetate (DB05288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as an injection into an anterior juxtascleral depot
Trial: NCT00788541
Drug: Anecortave Acetate Sterile Suspension, 3.75 mg/mL
DrugBank: Anecortave acetate (DB05288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as an injection into an anterior juxtascleral depot
Trial: NCT00683124
Drug: Losartan and nebivolol
RxNorm normalized name: valsartan and nebivolol
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebivolol is administered orally as pills. It is given preferentially once a day in the morning or, if not well tolerated because of hypotension, the total daily dosage is given in two administrations.~Losartan is administered orally as pills. It is given preferentially once a day or, if not well tolerated because of hypotension, the total daily dosage is given in two administrations
Trial: NCT00683124
Drug: Losartan
RxNorm normalized name: Losartan
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Losartan is administered orally as pills. It is given preferentially once a day or, if not well tolerated because of hypotension, the total daily dosage is given in two administrations
Trial: NCT00683124
Drug: Nebivolol
RxNorm normalized name: Nebivolol
DrugBank: Nebivolol (DB04861)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebivolol is administered orally as pills. It is given preferentially once a day in the morning or, if not well tolerated because of hypotension, the total daily dosage is given in two administrations
Trial: NCT00788541
Drug: Anecortave Acetate Sterile Suspension, 96 mg/mL
DrugBank: Anecortave acetate (DB05288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as an injection into an anterior juxtascleral depot
Trial: NCT00788541
Drug: Anecortave Acetate Sterile Suspension, 60 mg/ML
DrugBank: Anecortave acetate (DB05288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as an injection into an anterior juxtascleral depot
Trial: NCT02387606
Drug: JNJ-53718678
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive JNJ-53718678 as 20 milliliter (mL) (200 mg) or 50 mL (500 mg) oral solution (containing 10 mg JNJ-53718678 per mL) in Cohort 1. JNJ-53718678 dose in Cohort 2 will be decided based on Cohort 1 results. JNJ-53718678 as 7.5 mL (75 mg) oral solution (containing 10 mg JNJ-53718678 per mL) in Cohort 3.
Trial: NCT00701259
Drug: Lansoprazole
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole 15 mg once per day for 14 days
Trial: NCT00701259
Drug: Lansoprazole
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg once per day for 14 days
Trial: NCT00766675
Drug: Tramadol hydrochloride
RxNorm normalized name: Tramadol Hydrochloride
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tramadol hydrochloride oral tablet will be administered at a dose of 37.5 milligram as, once daily for Day 1-3, twice daily for Day 4-6 and thrice daily for Day 7-56.
Trial: NCT03099330
Drug: TQ-B3139
RxNorm normalized name: TQS-168
DrugBank: TQS-168 (DB18108)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQ-B3139 p.o. qd
Trial: NCT01698541
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tested generic
Trial: NCT01698541
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Original formulation used as comparator
Trial: NCT01053650
Drug: Paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clinical trial conducted in healthy volunteers, prospective, single center, randomized, open / hidden.
Trial: NCT00761670
Drug: amisulpride and risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: amisulpride tablet 400-800 mg/day risperidone tablet 4-8 mg/day
Trial: NCT01755442
Drug: AMG 151
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible subjects will be randomly assigned (1:1) to receive AMG 151 and matching placebo in 1 of 2 sequences over 2 treatment periods.
Trial: NCT02044848
Drug: Secukinumab
RxNorm normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02837640
Drug: levodopa-carbidopa
RxNorm normalized name: carbidopa / levodopa
DrugBank: Carbidopa (DB00190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sinemet 200/50 1/2 tablet b.i.d. for 2 days and then t.i.d for 6 months
Trial: NCT01946542
Drug: beet juice concentrate
DrugBank: Beet (DB10640)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose of beet juice concentrate, roughly 70 mL
Trial: NCT00089089
Drug: decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01906684
Drug: Acthar Gel
RxNorm normalized name: Acthar Gel
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients who present with MS relapse within 72 hours of onset will be recruited for study. Upon consent they will be administered Achtar Gel for 5-14 days as clinically appropriate.
Trial: NCT02780141
Drug: roxadustat
RxNorm normalized name: roxadustat
DrugBank: Roxadustat (DB04847)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Oral
Trial: NCT00217152
Drug: CellCept
RxNorm normalized name: Cellcept
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01503450
Drug: Olanzapine OD Tablets 5 mg
RxNorm normalized name: olanzapine Oral Tablet
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olanzapine OD Tablets 5 mg of Dr. Reddy's Laboratories Limited
Trial: NCT02068157
Drug: Porfimer Sodium
RxNorm normalized name: Porfimer Sodium
DrugBank: Porfimer sodium (DB00707)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02809755
Drug: 4% Lidocaine
RxNorm normalized name: Lidocaine 344 mg TOPICAL PATCH [Pain Relief 4% Lidocaine]
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03805984
Drug: INO-4500
RxNorm normalized name: INO
DrugBank: Inosine (DB04335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: INO-4500 will be administered ID on Day 0 and Week 4.
Trial: NCT03604679
Drug: SyB C-0501
RxNorm normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT03105479
Drug: Cadazolid
RxNorm normalized name: Cadazolid
DrugBank: Cadazolid (DB11847)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granules for oral suspension to be administered twice daily
Trial: NCT03105479
Drug: Vancomycin capsule
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsule containing 125 mg of vancomycin to be administered orally 4 times a day
Trial: NCT03105479
Drug: Vancomycin solution
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vancomycin powder to be administered as oral solution at a dose of 40 mg/kg/day, 3 to 4 times a day
Trial: NCT00910208
Drug: morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous morphine